Medicago has developed two proprietary technologies for the development of vaccines: its plant-based Proficia™ technology and its Virus-Like Particles (VLPs). Compared with traditional egg-based and cell production systems, plants are uniquely capable of efficient protein expression at very high yields. Proficia™ is a robust vaccine and antibody production system based on transient protein expression in plant leaves. Medicago’s VLPs mimic the native structure of a virus, allowing them to be recognized readily by the immune system without the core genetic material, making them non-infectious and unable to replicate.